Drug Trial Radar · NCT04640623
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
220
Actual
Start
Dec 18, 2020
Primary completion
Jul 3, 2025
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Nov 23, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab (Cohort 1), or TAR-200 alone (Cohort 2), or cetrelimab alone (Cohort 3) with Carcinoma in Situ (CIS), with or without concomitant high-grade Ta or T1 papillary disease; and disease-free survival (DFS) in participants treated with TAR-200 alone with papillary disease only (Cohort 4).
Conditions
- Urinary Bladder Neoplasms
Interventions
TAR-200Drug
TAR-200 will be administered transuretherally.
CetrelimabBiological
Cetrelimab will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohorts 1, 2, and 3: Overall Complete Response (CR) RateTime frame: From date of first dose up to clinical cut-off date 3rd July 2025 (up to 50 months)
- Cohort 4: Disease-free Survival (DFS)Time frame: From date of first dose up to clinical cut-off date 3rd July 2025 (up to 50 months)
Locations
144 sites in 16 countries. Site status is shown where the registry gives one.
Del Sol Research Management, LLC
Tucson, Arizona
University of Southern California
Los Angeles, California
Genesis Healthcare Partners - Genesis Research Greater Los Angeles
Sherman Oaks, California
The Urology Center of Colorado
Denver, Colorado
Foothills Urology - Golden Off
Golden, Colorado
DuPage Medical Group
Lisle, Illinois
Urology of Indiana
Greenwood, Indiana
Wichita Urology Group
Wichita, Kansas
Michigan Institute of Urology
Troy, Michigan
NYU Langone Health
New York, New York
SUNY Upstate Medical University
Syracuse, New York
Associated Medical Professionals
Syracuse, New York
Levine Cancer Institute
Charlotte, North Carolina
The Urology Group
Cincinnati, Ohio
Urologic Consultants of Southeastern Pennsylvania
Bala-Cynwyd, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania
Urology Associates, PC
Nashville, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
Urology Austin
Austin, Texas
University of Texas Southwestern Medical Center
Dallas, Texas
Urology San Antonio Research
San Antonio, Texas
Spokane Urology
Spokane, Washington
Flinders Medical Centre
Bedford Park, Australia
Eastern Health Research
Box Hill, Australia
Macquarie University Hospital
Sydney, Australia
AZ Sint-Lucas Brugge
Assebroek, Belgium
AZ Sint-Jan Brugge
Bruges, Belgium
Hopital Erasme
Brussels, Belgium
Algemeen ziekenhuis Maria Middelares
Ghent, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
Algemeen Ziekenhuis Delta
Roeselare, Belgium
AZ Nikolaas
Sint-Niklaas, Belgium
Exdeo Clinical Research Inc
Abbotsford British Columbia, British Columbia, Canada
William Osler Health System
Brampton, Ontario, Canada
Princess Margaret Hospital- UHN
Toronto, Ontario, Canada
McGill University Health Centre
Montreal, Quebec, Canada
Universite de Sherbrooke
Sherbrooke, Quebec, Canada
Hopital Pellegrin CHU Bordeaux
Bordeaux, France
Polyclinique Bordeaux Nord Acquitaine
Bordeaux, France
CHU Grenoble
Grenoble, France
Showing 40 of 144 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.